MDWD vs PMA Comparison

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

PMA Graphene Technology Group Inc, formerly Ming Shing Group Holdings Ltd, is a holding company engaged in wet trades works, including plastering, tile laying, brick laying, floor screeding and marble works. To a much lesser extent, it provides small-scale fitting out services, such as renovation works, and engages in trading of wines and spirits. Through its subsidiaries, it is mainly engaged in private sector projects in Hong Kong, involving private residential and commercial developments, while public sector projects mainly involve public residential developments, infrastructure and public facilities developments. The Company operates through two segments: Provision of Wet Trades Works and Trading of Wines and Spirits, with Trading of Wines and Spirits generating the maximum revenue.